This article highlights and emphasizes how new knowledge of mechanisms linked to the interleukin-23 (IL-23)/IL-17 pathway is relevant to the pathophysiology of axial spondyloarthritis (axSpA) and demonstrates how molecules in IL-23/IL-17 pathway provide novel therapeutic targets for axSpA patients.
INTRODUCTION
The term axial spondyloarthritis (axSpA) emerged in the revised Assessment in SpondyloArthritis international Society (ASAS) diagnostic criteria published in 2009 [1] . Looking beyond the New York criteria, which are limited to patients with radiographic changes, the ASAS criteria included a wider spectrum of patients with inflammatory back disease. A subsequent population-based study [2] in the United States found the prevalence of spondylarthritis (SpA) to be 1%, significantly higher than previous estimates and somewhat puzzling to practicing rheumatologists who evaluate far more rheumatoid arthritis (RA) than inflammatory back pain patients. It has now become apparent from several studies that focusing on ankylosing spondylitis (AS), which requires defined radiographic features in the sacroiliac joints, excludes a large population of patients with nonradiographic axSpA (nr-axSpA). These patients are more likely to be women and demonstrate normal C-reactive protein levels. Moreover, patients with nr-axSpA demonstrate similar disease activity and quality of life indices to patients with AS and in one observational study [3] , similar response and adherence to anti-tumor necrosis factor (TNF) agents. On the basis of these observations, some experts in the field eschew creating distinct disease subsets (nr-axSpA and AS) in favor of viewing these as different presentations of a single disease or as a continuum.
The finding that about 5% of patients with nr-axSpA go on to develop AS at 2 years provides support that the diseases may be distinct with unique phenotypes that would be best appreciated over the course of time.
Layered on this background of controversy regarding natural history, diagnosis and disease classification are the considerable advances in our understanding of disease pathogenesis of axial SpA. In particular, the discovery that the IL-23/IL-17 pathway is a central axis in the development and persistence of the disease unleashed a search for new targets that now form the basis for drug development in this area. Convincing evidence from animal models, translational studies and recent clinical trials underscores the importance and complexity of this pathway. In this review, we will discuss major recent advancements in the field about our understanding of IL-17/IL-23 molecular mechanisms and provide examples of how these discoveries catalyzed the development of effective therapies.
BRIEF OVERVIEW OF THE INTERLEUKIN-23/INTERLEUKIN-17 PATHWAY AND MAJOR PLAYERS
IL-17 is an immunologically important cytokine that was first identified as a transcript from murine lymphoid cells [4] . Subsequent studies established IL-17 not only as a key mediator of immune response against pathogens, but also as a potent mediator of inflammation and tissue damage in several autoimmune and inflammatory diseases [5] . Over the years, many other similar proteins have been discovered. Currently, the IL-17 family consists of six ligand members (IL-17A to IL-17F) that bind to five different receptors: IL-17RA, IL-17RB, IL-17RC, IL-17RD and IL-17RE that have been identified. Initially, a subset of CD4 þ T cells, now popularly known as Th17, was thought to be the major source of IL-17, but recent studies revealed that many other cell subsets including CD8 þ cytotoxic T cells [6] , gd T cells [7] , natural killer (NK) cells and innate lymphoid cells (ILCs) can also secrete high levels of IL-17 and other related cytokines, such as IL-22 and TNF-a. A model that incorporates elements of the IL-23/IL-17 pathway in axSpA pathogenesis is depicted in Fig. 1 .
Specific subsets of ILCs, that is type 3 ILCs (ILC3) were also recognized as another major source of IL-17A, IL-17F, IL-22 and other related cytokines [8] . Importantly, differentiation of IL-17-secreting cells is critically dependent on the presence of key inflammatory cytokines, IL-1b, IL-6, IL-23 and TGF-b. Among these, IL-23 appeared to be of great significance as studies revealed that IL-23 not only stabilizes the phenotype of Th17 cells [9, 10] , but also determines their function and pathogenic capacity [11] . IL-23 is predominantly secreted by activated macrophages and dendritic cells and plays deterministic functions in the differentiation of various subsets of IL-17-secreting cells [7, 11] .
THE IMPORTANCE OF THE INTERLEUKIN-23/INTERLEUKIN-17 PATHWAY IN THE PATHOGENESIS AXIAL SPONDYLOARTHRITIS
For well over a decade, the prevailing paradigm of AS pathogenesis has been centered on the dominance of the Th1 pathway and TNF-a. The efficacy of anti-TNF agents for axial disease at a time when no other therapies were active for this manifestation, provided strong support for this model. The discovery of IL-23 and other members of the IL-17 pathway, however, unveiled alternative mechanisms and targets. Although preclinical studies suggested this pathway to be operative in both RA and spondyloarthritis, human translational reports and clinical trials demonstrated that IL-23 and IL-17 are key cytokines in only axSpA and PsA. These exciting discoveries provide unparalleled opportunities to decipher disease pathogenesis and to uncover new therapeutic targets.
Findings from Genetic, Epigenetic, In-Vitro and Recent Animal Studies association studies, which showed that various polymorphisms in the IL-23 receptor (IL23R) gene were associated with AS [12] . Genome-wide association revealed that IL23R variant rs11209026 (Arg381Gln) offers protection against AS [12] by showing decreased STAT3 phosphorylation [13] , which ultimately leads to a selective impairment of IL-17 production [14] . Many other IL-23/IL-17 pathwayrelated genes such as IL-6R, IL-12B, IL-27, CARD9, STAT3 and TYK2 have also been implicated in AS [15] indicating the potential importance of the IL-I7/IL-23 pathway in the axSpA. Uddin et al. [16 && ] applied an integrative genomics approach to show that AS risk alleles overlap with global immunerelated pathways and Th17-related genes in AS pathogenesis. Integration of genetic and epigenetic fine mapping of causal variants related to autoimmune diseases further revealed the relatedness of AS, psoriasis and inflammatory bowel disease; all three disorders demonstrated a Th17 cell-specific epigenetic signature for the known variants [17 && ]. Previous animal studies [18, 19] established the essential role of IL-23/IL-17 pathway in ankylosing enthesitis and bone remodeling. Animal studies also indicated that IL-23-driven inflammation can lead to new bone formation in AS [20] . The finding from the proteoglycan-induce spondylitis (PGISp) mouse model of AS further suggests that inflammation and new bone formation unfold sequentially and not in a parallel sequence. Inflammation precedes intervertebral disk destruction and serves as a prerequisite for axial disease progression [21 & ]. Findings from this study [21 & ] further suggest that inflammation drives the increased osteoproliferation, which subsequently leads to altered bone phenotypes in AS. Additional support for the importance of IL-17 in spondylitis is supported by prophylactic administration of anti-IL-17 antibodies, which block the development of ankylosis in male SKG1 mice [22] . Taken together, these studies indicate that the IL-23/IL-17 pathway is centrally involved in the pathogenesis of axSpA and that targeting this pathway may be an effective strategy in this group of disorders. is derived from studies of human blood cells and joint tissues. Analysis of samples from AS patients revealed increased numbers of Th17 [23, 24] , Th22 [23] and gd T cells [25] in the peripheral blood and an increased level of IL-17 [26] [27] [28] and IL-23 [27, 29, 30] in the serum and synovium. It has been also reported that the KIR3DL2 þ Th17 cells, responsive to HLA-B27 homodimers, are increased in the peripheral blood and synovium of AS patients [31] , and the interaction of KIR3DL2 with HLA-B27 dimers promotes survival and the IL-17 production capacity of the KIR3DL2 expressing Th17 cells [31] . ]. It is important to mention that this finding contradicts earlier data that reported either no difference [33] or decreased frequencies of Th17 cells in peripheral blood of nr-axSpA patients [34] compared with the healthy controls. These divergent findings may be due to differences in sex composition, genetic background or immunologic methods. Additional studies are necessary to resolve these conflicting results.
Preclinical and Translational Studies
It is well established that compared with women with AS, men are more likely to have radiographic changes in the SI joints and increased CRP, but the two sexes experience similar levels of pain and functional impairment [35] . The underlying biology responsible for these differences is unknown. Investigators in Toronto examined sexual dimorphism in the Th17 signature of men and women with AS [36 && ]. They analyzed cells present in whole blood collected from disease matched cohorts of male and female patients and age-matched healthy controls. Their analysis revealed that IL-17A and Th17 cell frequency was elevated in male but not female AS patients and these findings were further supported by results obtained by global gene expression analysis using microarray. In addition, male and female AS patients demonstrated shared gene expression patterns although males showed altered gene expression patterns not observed in females. These findings suggest divergent mechanisms of disease in male and female AS patients and may account for the more severe bone phenotypes often observed in males. Interestingly, in this case, the sex bias in terms of IL-17 pathway-related gene signatures was shown to be independent of sex hormone levels. Thus, this new finding may reveal the key pathways responsible for the divergent phenotypes in the sexes. Additional studies are required, however, to better understand the underlying biology responsible for the sexual dimorphism in the Th17 signature in AS.
Past evidence from human studies [33, 37] also suggested that in AS, apart from Th17, innate immune cells can also serve as a major source of IL-17 especially in target tissues. The recognition that ILCs promote inflammation in a range of disorders is now apparent. In relation to SpA, emerging evidence indicates that ILC3 cells that respond to IL-23 also serve as major sources of IL-17, IL-22 and other related cytokines, and this population is expanded in the joints of PsA but not RA patients [38] . In AS patients, IL-17 and IL-22-secreting NKp44 þ ILC3 cells were expanded in the peripheral blood, gut, synovial fluid and bone marrow [39 && ]. Interestingly, ILC3 cells present in peripheral blood, synovial fluid and bone marrow of AS patients expressed the a3b7 integrin indicating these cells likely originated in the gut. The ILC3 cells produced distinct cytokines in individual tissue compartments, although IL-22 secretion was elevated in most specimens, while only a small percentage of cells in peripheral blood expressed IL-17 alone or in combination with IL-22. These data highlight the potential importance of innate immune cells in disease pathogenesis and raise the possibility that they may serve as therapeutic targets.
The Role of the Gut Microbiome and Intestinal Inflammation in Axial Spondyloarthritis
A growing body of literature supports strong links between gut inflammation and spondylitis (reviewed in [40, 41] ) and implicates both HLA-B27 alleles and the IL-23/IL-17 axis as key pathogenic factors. Studies in transgenic rats carrying the human HLA-B27 and b2 microglobulin genes revealed that intestinal inflammation in these rats concurrently occurs with elevated expression of IL-23 and IL-17 in the colonic tissues [42] . Recent studies further revealed altered gut microbiota in transgenic HLA-B27 rats compared with wild-type littermates [43] . Of particular relevance was the finding of dysbiosis in the gut microbiome of AS patients characterized by higher abundance of five families of bacteria, Bacteroidaceae, Lachnospiraceae, Porphyromonadaceae, Rikenellaceae and Ruminococcaceae, and decreased abundance of two families of bacteria, Prevotellaceae and Veillonellaceae, in the terminal ileum of AS patients compared with healthy controls [44 && ]. Altered bacterial flora have also been reported in PsA [45] and IBD [46] [47] [48] . Interactions of cell surface ligands with specific microbes can induce differentiation of IL-17 and IL-22-secreting cells [49, 50] programming their pathogenic capacity [51] . Collectively, these findings implicate microbial dysbiosis as triggers of altered homeostasis through the IL-23/IL-17 pathway resulting in gut and joint inflammation.
In support of a gut-spondylitis connection are reports of a high prevalence of gut inflammation in axSpA identified in the Ghent Inflammatory Arthritis and spoNdylitis cohorT patient cohort [52] . Ileocolonscopy combined with MRI imaging studies showed that the degree of spinal inflammation in axSpA patents correlated well with chronic but not acute gut inflammation in patients without gastrointestinal symptoms [53] . Increased expression of IL-23 had been already noted in the gut of AS patients when compared with healthy controls [54] . A recent study [55 & ] further revealed that AS patients display altered DCs and T-cell populations that further implicate the role of IL-23 in gut inflammation. In another report, IL-17 and IL-22 producing ILC3 cells were present in greater frequency in the gut of AS patients compared with healthy controls [39 && ]. These ILC3 cells appeared to be predominantly expanded in the more inflamed gut of the AS patients, and TNF-blocking agents were shown to be effective in reducing their abundance in the gut [39 && ]. These above mentioned results indicate the existence of a gut-joint/spine axis in AS whereby ILC3 may be critical effectors secreting IL-17, IL-22 and possibly other inflammatory cytokines.
TARGETING THE INTERLEUKIN-23/ INTERLEUKIN-17 PATHWAY FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
As previously mentioned, anti-TNF-a blocking agents were the only effective way to treat axSpA patients who failed first line of therapy with NSAIDs and physical therapy for over a decade. Moreover, up to 50% of patients with active axSpA do not achieve primary endpoints despite treatment with NSAIDs and/or anti-TNF-a-blocking agents [56 && ]. Moreover, recent clinical trials also demonstrated that targeting other cytokines or molecules such as IL-1 [57] , IL-6 [58] or enzyme phosphodiesterase 4 [59] is not effective in axSpA. Fortunately, results from clinical trials show that targeting the IL-23/IL-17 pathway holds great promise for treatment of axSpA (Fig. 2) . Approved therapeutic drugs along with agents currently in clinical trials and in the pipeline that targets molecules in the IL-23/IL-17 pathways are discussed below and outlined in Table 1 .
Interleukin-23 Antagonists: Ustekinumab and Bi655066
IL-23 is composed of two protein subunits, p19 and p40. Although the p19 subunit is unique to IL-23, the p40 subunit also associates with the protein subunit, p35 to form IL-12. Therapeutic agents have been developed to neutralize IL-23 by binding to either of these two subunits. Ustekinumab is a
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IL Targeting the IL-23/IL-17 axis in axSpA Paine and Ritchlin monoclonal antibody that binds to the p40 subunit and serves as a dual antagonist of IL-12 and IL-23. Ustekinumab is effective and well tolerated in patients with plaque psoriasis [60] and in PsA patients [61] . Indeed, the drug is approved in the United States for both diseases. Importantly, ustekinumab inhibits radiographic progression in PsA patients [62] . In a phase II proof-of-concept study (TOPAS), the efficacy and safety of ustekinumab in AS were analyzed in 20 patients. In this study [63 & ], 65% of the patients achieved the ASAS40 response and 55% reached BASDAI50 response at week 24. Ustekinumab administration was also shown to be substantially effective in reducing active inflammation of the sacroiliac joints and the spine (41 and 31% reductions, respectively) in treatment responders based on MRI assessment [63 & ]. In an ongoing clinical trial (ClinicalTrials.gov ID -NCT02407223), the efficacy and safety of ustekinumab to treat patients with active nr-axSpA as well as patients with active radiographic axSpA, who are naive or refractory to anti-TNF-a agents (Clin-icalTrials.gov ID -NCT02437162 and NCT02438787 respectively), are underway. Similarly, a fully human IgG1 monoclonal antibody against the p19 subunit of IL-23, BI655066, is under investigation in a 48-week phase III randomized, doubleblind, placebo-controlled clinical trial in patients with AS (ClinicalTrials.gov ID -NCT02047110).
Interleukin-17 Antagonists: Secukinumab, Ixekizumab and Brodalumab
At present, two antibodies that inhibit IL-17A have been developed: secukinumab is approved for AS and ixekizumab is in phase III trials. Secukinumab is a fully human monoclonal antibody that selectively binds and neutralizes IL-17A. In an earlier phase II randomized double blinded placebo-controlled trial, secukinumab was effective in controlling symptoms of AS [64] . Subsequent phase III trials provided further proof of its efficacy in AS patients [65 && ]. In the MEASURE 1 trial, 371 patients with active AS were given intravenous loading followed by monthly subcutaneous dosing. The primary outcome measure, ASAS20 response rate at week 16, was 61, 60 and 29%, respectively, for patients treated with 150 or 75 mg of secukinumab or placebo, showing significant difference between active drug and placebo (P < 0.001) [65 && ]. In MEASURE 2, the study design used subcutaneous loading and monthly dosing, and the ASAS 20 response rates at 16 weeks were 61 and 41% with secukinumab at a dose of 150 and 75 mg and 28% for placebo [65 && ]. A recent study [66] using MRI endpoints further revealed that secukinumab treatment reduces inflammation in AS patients detected even after 2 years. Taken together, these two studies demonstrated that secukinumab is efficacious for treatment of AS patients, and additional studies are planned for patients with nr-axSpA. Further studies will be also needed to compare efficacy of secukinumab with approved anti-TNF agents. Nonetheless, secukinumab will likely benefit patients with axSpA and is also effective in anti-TNF inadequate responders, although the response is lower than in biologic naive patients. Similarly to secukinumab, ixekizumab is another humanized monoclonal antibody that binds and neutralizes IL-17A. A phase III trial of ixekizumab in AS (COAST-W, ClinicalTrials.gov ID -NCT02696798) is underway. A phase III clinical trial to test the efficacy and safety of an anti-IL-17R monoclonal antibody, brodalumab, in PsA was canceled (ClinicalTrials.gov ID -NCT02429882) because of increased suicidal ideation and completed suicides noted in psoriasis clinical trials [67] .
Novel Therapeutic Strategies to Inhibit the Interleukin-23/Interleukin-17 Pathway COVA322 is another such antibody fusion protein that can bind to TNF-a and IL-17A [68] . These dual agents will be tested for efficacy and safety axSpA in future clinical trials. Finally, CBP30, a selective small molecule inhibitor of CBP/p300 bromodomains, was shown to be effective in suppressing Th17 cytokine production from T cells of AS patients as well as of healthy controls [69] . Future clinical trials are anticipated.
FUTURE DIRECTIONS
Despite the many advances associated with elucidation of IL-23/IL-17 pathway in axSpA pathogenesis, many challenges remain that hold great promise for additional advances and improved therapeutic opportunities ( Table 2) . A major challenge is how specific differences in IL-23/IL-17 pathway gene signatures in male and female axSpA patients may translate into more personalized treatment strategies. Also, our understanding of the steps leading to new bone formation in axSpA is still very limited, although animal studies point to a possible contribution from IL-22. Further studies will be needed to clarify the role of not only IL-22, but also IL-17A, IL-17F, IL-23 and other key cytokines in osteoproliferation -a process that limits function in axSpA. Current studies provide a tantalizing glimpse of the relationship between gut dysbiosis and axial inflammation, but we require confirmatory data from both preclinical studies and human tissues to confirm the specifics of the proposed gut-axial disease axis. Moreover, it is imperative from both a pathogenesis and therapeutic perspective to determine whether alteration in gut microbial composition drives immunological and pathological alterations or is a result of these changes. It will also be of central importance to define the complex relationship between TNF-a and IL-23/IL-17 pathways in order to develop more effective treatment strategies, possibly combining these agents, in the near future. Similarly, the efficacy and safety of IL-17F, IL-22 and IL-23 inhibition require investigation in patients with axSpA. One of the biggest challenges in this group of disorders that targets young adults most commonly is successful strategies to ensure early diagnosis, and several approaches are underway around the globe to address it. Future studies will undoubtedly uncover additional cellular and serum biomarkers and imaging strategies to correctly diagnose axSpA in the early stages. Similarly, such biomarkers will facilitate patient stratification to optimize treatment and to monitor therapeutic response. Targeting the IL-23/IL-17 axis in axSpA Paine and Ritchlin CONCLUSION Over the last 5 years, we have witnessed how discoveries at the bench which redefined immunology can also improve human health. New knowledge regarding the importance of the IL-23/IL-17 pathway in axSpA paved the way for new therapeutic options that are either in the clinic or in clinical trials. Despite these advances, many unresolved issues remain and require further investigation. Recent efforts are directed toward the development of agents that block additional molecules in this pathway, and we expect that some of these will prove successful therapies in axSpA. Additional studies are required to further delineate the role of innate cells (ILC3, NK and CD4 -) and gut inflammation in axSpA pathogenesis and how cytokines such as IL-17, IL-22 and IL-23 regulate inflammation and bone formation in axSpA. Finally, identification of new biomarkers will not only permit earlier diagnosis, but also help direct treatment selection of biologic therapies including those that target the IL-23/IL-17 pathway in axSpA.
